logo

Epix Pharmaceuticals, Inc. (EPIX)



Trade EPIX now with
  Date
  Headline
10/7/2021 9:21:33 AM ESSA Pharma Announces Presentation Of Preclinical Data Characterizing Mechanism Of Action Of EPI-7386
8/16/2021 7:05:17 AM ESSA Pharma Q3 Net Loss $8.8 Mln Vs. Net Loss $4.9 Mln Last Year
4/28/2021 7:19:15 AM ESSA Collaborates With Bayer To Evaluate Combination Of EPI-7386 And Darolutamide In MCRPC Cancer
2/17/2021 10:58:04 PM ESSA Pharma Announces Pricing Of Public Offering Of 4.83 Mln Common Shares At $27/Shr
2/11/2021 8:11:43 AM ESSA Pharma Presents Favorable Initial Phase 1 Pharmacology Data Of EPI-7386 For Advanced Forms Of Prostate Cancer
2/11/2021 7:58:19 AM ESSA Pharma Q1 Net Loss $6.5 Mln Or $0.20/shr Vs Loss Of $4.6 Mln Or $0.22/shr Prior Year
1/13/2021 7:23:20 AM ESSA Pharma Enters Clinical Collaboration And Supply Agreement With Janssen Research & Development, LLC
1/13/2021 7:18:49 AM ESSA, Janssen To Evaluate EPI-7386 Combination For Patients With Metastatic Castration-Resistant Prostate Cancer
1/13/2021 7:01:56 AM ESSA Pharma Enters Clinical Collaboration With Janssen To Evaluate EPI-7386 Combination For Patients With MCRPC
9/14/2020 7:15:34 AM ESSA Pharma: FDA Grants Fast Track Designation To EPI-7386 For Metastatic Castration-Resistant Prostate Cancer
8/6/2020 8:52:54 PM ESSA Pharma Q3 Net Loss Of $4.9 Mln Or $0.24/shr Vs. Net Loss Of $3.3 Mln Or $0.52/shr Prior Year
7/31/2020 10:17:48 AM ESSA Pharma Completes Public Offering For Aggregate Gross Proceeds Of US$48.99 Mln
7/28/2020 9:50:32 PM ESSA Pharma Announces Pricing Of Underwritten Public Offering Of 7.10 Mln Shares At US$6.00/shr
7/15/2020 7:09:07 AM ESSA Pharma Announces First Patient Dosed In A Phase 1 Clinical Trial Of EPI-7386 For MCRPC
6/22/2020 7:35:10 AM ESSA Pharma Presents Therapeutic Potential Of EPI-7386 At 2020 AACR